Concert Pharmaceuticals, Inc introduces CTP-543, Oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata in adult patients.
Alopecia areata, is an autoimmune disorder in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.It affects approximately 700,000 Americans. In this particular disease scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp appearing throughout life infecting both men and women. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.
CTP-543therapy is applicable for the treatment of alopecia areata. Treatment with CTP-543 was well tolerated by patients.
FDA Breakthrough Therapy Designation for CTP-543was done based on the positive results from Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.
US Food and Drug Administration (FDA)grants Breakthrough Therapy Designation for CTP-543 for the treatment of alopecia areata.
